Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

Lisa Vermunt; Alegria J. L. van Paasen; Charlotte E. Teunissen; Philip Scheltens; Pieter Jelle Visser; Betty M. Tijms; Alzheimer's Disease Neuroimaging Initiative (ADNI)

doi:10.1212/WNL.0000000000007609

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

Lisa Vermunt^*
, Alegria J. L. van Paasen
, Charlotte E. Teunissen
, Philip Scheltens
, Pieter Jelle Visser
, Betty M. Tijms
, Alzheimer's Disease Neuroimaging Initiative (ADNI)

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective

To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).

Methods

We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.

Results

Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 +/- 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels.

Conclusion

In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.

Original language	English
Pages (from-to)	E2699-E2705
Number of pages	7
Journal	Neurology
Volume	92
Issue number	23
DOIs	https://doi.org/10.1212/WNL.0000000000007609
Publication status	Published - 4 Jun 2019

Keywords

DEMENTIA
MILD COGNITIVE IMPAIRMENT
NEUROIMAGING INITIATIVE ADNI
PROGRESSION
REVERSION

Access to Document

10.1212/WNL.0000000000007609Licence: CC BY-NC-ND

Cite this

@article{5dc0b0670b3b48ebac54dac4d5050cab,

title = "Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal",

abstract = "ObjectiveTo identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).MethodsWe selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.ResultsSeventy-seven (10\%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 +/- 2.2 years, 16 (24\%) progressed to MCI, and 3 (5\%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels.ConclusionIn MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.",

keywords = "DEMENTIA, MILD COGNITIVE IMPAIRMENT, NEUROIMAGING INITIATIVE ADNI, PROGRESSION, REVERSION",

author = "Lisa Vermunt and \{van Paasen\}, \{Alegria J. L.\} and Teunissen, \{Charlotte E.\} and Philip Scheltens and Visser, \{Pieter Jelle\} and Tijms, \{Betty M.\} and \{Alzheimer's Disease Neuroimaging Initiative (ADNI)\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",

year = "2019",

month = jun,

day = "4",

doi = "10.1212/WNL.0000000000007609",

language = "English",

volume = "92",

pages = "E2699--E2705",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams \& Wilkins",

number = "23",

}

TY - JOUR

T1 - Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

AU - Vermunt, Lisa

AU - van Paasen, Alegria J. L.

AU - Teunissen, Charlotte E.

AU - Scheltens, Philip

AU - Visser, Pieter Jelle

AU - Tijms, Betty M.

AU - Alzheimer's Disease Neuroimaging Initiative (ADNI)

PY - 2019/6/4

Y1 - 2019/6/4

N2 - ObjectiveTo identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).MethodsWe selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.ResultsSeventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 +/- 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels.ConclusionIn MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.

AB - ObjectiveTo identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).MethodsWe selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.ResultsSeventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 +/- 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels.ConclusionIn MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.

KW - DEMENTIA

KW - MILD COGNITIVE IMPAIRMENT

KW - NEUROIMAGING INITIATIVE ADNI

KW - PROGRESSION

KW - REVERSION

U2 - 10.1212/WNL.0000000000007609

DO - 10.1212/WNL.0000000000007609

M3 - Article

C2 - 31068481

SN - 0028-3878

VL - 92

SP - E2699-E2705

JO - Neurology

JF - Neurology

IS - 23

ER -

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

Abstract

Keywords

Access to Document

Fingerprint

Cite this